Compare Gilead Sciences, Inc. (GILD) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SAP SE — how do they compare? Gilead Sciences, Inc. trades at $133.04 (market cap $163.51B), while SAP SE trades at $157.25 (market cap $182.13B). The key difference: Gilead Sciences, Inc. and SAP SE are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | SAP | |
|---|---|---|
Market Cap | $163.51B | $182.13B |
Sector | Health | Technology |
52-Week High | $155.80 | $308.61 |
52-Week Low | $108.22 | $148.06 |
Enterprise Value | $178.05B | $179.64B |
Dividend Yield | 2.49% | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SAP's stock is trading at $154.81, down 3.23% on the day, amid a broader bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, a robust 19.58% net income margin, and accelerating cloud revenue growth of 27%. Recent news highlights a resolved EU antitrust investigation and strategic cost controls to fund AI investments, though the stock faces near-term technical pressure.
The investment case balances strong profitability and a bullish analyst consensus with a price target implying ~48% upside against near-term technical weakness and competitive AI spending pressures. The company's transformation to cloud and AI presents a long-term opportunity, but execution on cost discipline and market share retention are key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
